Provided by Tiger Trade Technology Pte. Ltd.

ANI Pharmaceuticals

76.31
+0.01500.02%
Volume:22.16K
Turnover:1.68M
Market Cap:1.71B
PE:22.95
High:76.86
Open:76.00
Low:75.18
Close:76.29
52wk High:99.50
52wk Low:56.71
Shares:22.47M
Float Shares:20.38M
Volume Ratio:1.00
T/O Rate:0.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):3.32
EPS(LYR):3.32
ROE:16.16%
ROA:3.82%
PB:3.17
PE(LYR):22.98

Loading ...

How Investors May Respond To ANI Pharmaceuticals (ANIP) Analysts’ Bullish Earnings and Revenue Forecasts

Simply Wall St.
·
Nov 04, 2025

ANI Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 7, 2025, at 8:30 a.m. ET

GlobeNewswire
·
Oct 24, 2025

ANI Pharmaceuticals Announces NEW DAY Clinical Trial Results to be Presented in Late-Breaking Oral Presentation at the American Academy of Ophthalmology 2025 Meeting

GlobeNewswire
·
Oct 16, 2025

ANI Pharmaceuticals (ANIP): Exploring Valuation After Year-to-Date 60% Share Price Surge

Simply Wall St.
·
Oct 15, 2025

Leerink Partners Sticks to Their Buy Rating for ANI Pharmaceuticals (ANIP)

TIPRANKS
·
Oct 15, 2025

ANI Pharmaceuticals SVP Meredith Cook Reports Sale of Common Shares

Reuters
·
Oct 15, 2025

ANI Pharmaceuticals Is Maintained at Hold by Truist Securities

Dow Jones
·
Oct 09, 2025

ANI Pharmaceuticals price target raised to $90 from $77 at Truist

TIPRANKS
·
Oct 09, 2025

Truist Raises Price Target on ANI Pharmaceuticals to $90 From $77, Keeps Hold Rating

MT Newswires Live
·
Oct 09, 2025

ANI Pharmaceuticals Completes Mandatory Conversion of Preferred Shares

TIPRANKS
·
Sep 27, 2025

ANI Pharmaceuticals Converts All 25,000 Series A Preferred Shares Into 602,900 Common Shares Through Two Transactions

Reuters
·
Sep 27, 2025

H.C. Wainwright Sticks to Their Buy Rating for ANI Pharmaceuticals (ANIP)

TIPRANKS
·
Sep 26, 2025

ANI Pharmaceuticals Is Maintained at Overweight by JP Morgan

Dow Jones
·
Sep 24, 2025

U.S. RESEARCH ROUNDUP-Autozone, Pfizer, Valley National Bancorp

Reuters
·
Sep 24, 2025

ANI Pharmaceuticals (ANIP): Assessing Valuation Following Strong 2025 Revenue Guidance Update

Simply Wall St.
·
Sep 24, 2025

Krista Davis, SVP and Chief HR Officer, Reports Disposal of Common Shares of ANI Pharmaceuticals Inc

Reuters
·
Sep 24, 2025

How ANI Pharmaceuticals’ Ambitious 2025 Revenue Outlook Will Impact ANIP Investors

Simply Wall St.
·
Sep 22, 2025

ANI Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Sep 17, 2025

HC Wainwright Adjusts ANI Pharmaceuticals Price Target to $121 From $93, Maintains Buy Rating

MT Newswires Live
·
Sep 17, 2025

ANI Pharmaceuticals price target raised to $121 from $93 at H.C. Wainwright

TIPRANKS
·
Sep 17, 2025